Literature DB >> 20828282

Duloxetine for the treatment of fibromyalgia.

Cheryl L Wright1, Scott D Mist, Rebecca L Ross, Kim D Jones.   

Abstract

This article presents a brief review of the physiologic abnormalities seen in fibromyalgia, current theories of widespread pain, and treatment options, including emerging therapeutics, with a focus on the use of duloxetine to manage fibromyalgia symptoms. Major clinical trials that examine the efficacy and effectiveness of duloxetine to date are reviewed, and safety issues are discussed.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20828282      PMCID： PMC3056054          DOI： 10.1586/eci.10.64

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN： 1744-666X            Impact factor:   4.473


  96 in total

Review 1.  Opioids for chronic pain: molecular and genomic basis of actions and adverse effects.

Authors:  Sam H Ahmedzai; Jason Boland
Journal:  Curr Opin Support Palliat Care       Date:  2007-08       Impact factor: 2.302

Review 2.  Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?

Authors:  David G S Perahia; Yili L Pritchett; Durisala Desaiah; Joel Raskin
Journal:  Int Clin Psychopharmacol       Date:  2006-11       Impact factor: 1.659

3.  Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia.

Authors:  Samuel A McLean; David A Williams; Phyllis K Stein; Richard E Harris; Angela K Lyden; Gail Whalen; Karen M Park; Israel Liberzon; Ananda Sen; Richard H Gracely; James N Baraniuk; Daniel J Clauw
Journal:  Neuropsychopharmacology       Date:  2006-08-23       Impact factor: 7.853

4.  Selective serotonin reuptake inhibitors: measurement of effect on platelet function.

Authors:  Donna Jo McCloskey; Teodor T Postolache; Bernard J Vittone; Khanh L Nghiem; Jude L Monsale; Robert A Wesley; Margaret E Rick
Journal:  Transl Res       Date:  2007-11-20       Impact factor: 7.012

5.  A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia.

Authors:  Lesley M Arnold; I Jon Russell; E W Diri; W Rachel Duan; James P Young; Uma Sharma; Susan A Martin; Jeannette A Barrett; George Haig
Journal:  J Pain       Date:  2008-06-03       Impact factor: 5.820

6.  The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial.

Authors:  Philip J Mease; Daniel J Clauw; R Michael Gendreau; Srinivas G Rao; Jay Kranzler; Wei Chen; Robert H Palmer
Journal:  J Rheumatol       Date:  2009-02       Impact factor: 4.666

Review 7.  Exercise interventions in fibromyalgia: clinical applications from the evidence.

Authors:  Kim D Jones; Ginevra L Liptan
Journal:  Rheum Dis Clin North Am       Date:  2009-05       Impact factor: 2.670

Review 8.  EULAR evidence-based recommendations for the management of fibromyalgia syndrome.

Authors:  S F Carville; L Arendt-Nielsen; S Arendt-Nielsen; H Bliddal; F Blotman; J C Branco; D Buskila; J A P Da Silva; B Danneskiold-Samsøe; F Dincer; C Henriksson; K G Henriksson; E Kosek; K Longley; G M McCarthy; S Perrot; M Puszczewicz; P Sarzi-Puttini; A Silman; M Späth; E H Choy
Journal:  Ann Rheum Dis       Date:  2007-07-20       Impact factor: 19.103

9.  Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial.

Authors:  Jon I Russell; Philip J Mease; Timothy R Smith; Daniel K Kajdasz; Madelaine M Wohlreich; Michael J Detke; Daniel J Walker; Amy S Chappell; Lesley M Arnold
Journal:  Pain       Date:  2008-04-18       Impact factor: 6.961

10.  Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials.

Authors:  Ernest H S Choy; Philip J Mease; Daniel K Kajdasz; Madelaine M Wohlreich; Paul Crits-Christoph; Daniel J Walker; Amy S Chappell
Journal:  Clin Rheumatol       Date:  2009-06-18       Impact factor: 2.980
View more
  7 in total

Review 1.  The P2X4 Receptor: Cellular and Molecular Characteristics of a Promising Neuroinflammatory Target.

Authors:  Reece Andrew Sophocleous; Lezanne Ooi; Ronald Sluyter
Journal:  Int J Mol Sci       Date:  2022-05-20       Impact factor: 6.208

2.  Managing Bipolar Disease Complicated with Psychosis in Conjunction with Polypharmacy, Parkinson's Disease, and Multiple Comorbidities.

Authors:  Ricardo Irizarry; Ariel Sosa Gomez; Simeon Miles; Jean Tamayo Acosta
Journal:  Case Rep Psychiatry       Date:  2022-05-05

3.  Targeting Pathological Tau by Small Molecule Inhibition of the Poly(A):MSUT2 RNA-Protein Interaction.

Authors:  Jeremy D Baker; Rikki L Uhrich; Timothy J Strovas; Aleen D Saxton; Brian C Kraemer
Journal:  ACS Chem Neurosci       Date:  2020-07-09       Impact factor: 4.418

Review 4.  The search for novel analgesics: targets and mechanisms.

Authors:  Tony L Yaksh; Sarah A Woller; Roshni Ramachandran; Linda S Sorkin
Journal:  F1000Prime Rep       Date:  2015-05-26

Review 5.  Genomic Medicine: Lessons Learned From Monogenic and Complex Bone Disorders.

Authors:  Katerina Trajanoska; Fernando Rivadeneira
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-09       Impact factor: 5.555

6.  Predictors of duloxetine adherence and persistence in patients with fibromyalgia.

Authors:  Zhanglin Cui; Yang Zhao; Diego Novick; Douglas Faries
Journal:  J Pain Res       Date:  2012-06-22       Impact factor: 3.133

Review 7.  Fibromyalgia: Recent Advances in Diagnosis, Classification, Pharmacotherapy and Alternative Remedies.

Authors:  Massimo E Maffei
Journal:  Int J Mol Sci       Date:  2020-10-23       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.